^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
PancraGEN®

Type:
Laboratory Developed Test
Related tests:
Evidence

News

2ms
USING DNA ANALYSIS AS A DIAGNOSTIC TOOL FOR PANCREATIC CYST MANAGEMENT (DDW 2024)
However, this study shows the increase in sensitivity in detection of cysts with IPMN/MCN pathology by combining size, CEA, and DNA analysis. These findings can validate serial surveillance by EUS with FNA, as DNA and CEA levels can morph over time and also provide improved guidance on potential premalignant mucinous cysts.
KRAS (KRAS proto-oncogene GTPase) • GNAS (GNAS Complex Locus)
|
KRAS mutation • GNAS mutation
|
PancraGEN®
10ms
Interpace Biosciences releases preliminary record second quarter 2023 business results; updates status of PancraGEN® reimbursement (Interpace Biosciences Press Release)
"On July 6, 2023, Novitas Solutions, Inc. announced that it was rescinding implementation of the Genetic Testing for Oncology LCD (L39365) so that it will not become effective on July 17, 2023. As a result, Interpace is able to continue offering PancraGEN..."
Medicare • Reimbursement
|
PancraGEN®
11ms
Interpace expects to stop offering PancraGEN® Test due to CMS decision to end reimbursement as of July 17, 2023 (Interpace Biosciences Press Release)
"Interpace Biosciences, Inc...announced that the Centers for Medicare & Medicaid Services (CMS) issued the final Local Coverage Determination (LCD) of Genetic Testing for Oncology (L39365) which establishes non-coverage for the Company’s widely used PancraGEN® test effective July 17, 2023. Commercially available in its current form since 2013, PancraGEN is a DNA-based molecular diagnostic test that uniquely assesses the risk of pancreatic cancer posed by pancreatic cysts and is used to rule-in and rule-out (risk-stratify) the disease."
Medicare • Reimbursement
|
PancraGEN®